Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Patritumab deruxtecan
Synonyms
Therapy Description

U3-1402 is an antibody drug conjugate comprised of an ERBB3 (HER3) antibody and Exatecan, which once internalized may result in apoptotic cell death (Journal of Thoracic Oncology, 12;11S2, 2017).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Patritumab deruxtecan U3-1402|HER3-DXd|U3 1402|U31402 HER3 (ERBB3) Antibody 17 Patritumab deruxtecan (U3-1402) is an antibody-drug conjugate (ADC) comprised of an ERBB3 (HER3) antibody and Exatecan, which once internalized may result in apoptotic cell death (Journal of Thoracic Oncology, 12;11S2, 2017, PMID: 31395690, PMID: 31661465, PMID: 31471314).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04610528 Phase I Patritumab deruxtecan A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3) Recruiting ESP 0
NCT04965766 Phase II Patritumab deruxtecan Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST) Recruiting FRA 0
NCT04619004 Phase II Patritumab deruxtecan HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 9
NCT02980341 Phase Ib/II Patritumab deruxtecan Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer Active, not recruiting USA 1
NCT04699630 Phase II Patritumab deruxtecan A Study of U3-1402 in Subjects With Metastatic Breast Cancer Recruiting USA 0
NCT04479436 Phase II Patritumab deruxtecan A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer Terminated USA | ITA | FRA | ESP | BEL 3
NCT03260491 Phase I Patritumab deruxtecan U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer Active, not recruiting USA | ESP 4
NCT04676477 Phase I Patritumab deruxtecan Osimertinib + Patritumab deruxtecan Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer Recruiting USA 1
NCT05338970 Phase III Patritumab deruxtecan A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 13


Additional content available in CKB BOOST